At Sunovion, targeted science is at the core of everthing we do—targeted science in the service of the patient.
Sunovion currently specializes in two well-defined therapeutic categories: respiratory diseases and disorders of the central nervous system. Our dynamic drug discovery program is actively investigating new ways to meet the unmet needs of underserved patients within these two therapeutic areas.
Our 25 years of North American experience encompasses a strong track record in isomer technology, discovery research, and successfully bringing drugs to market. Our predecessor company in the U.S, Sepracor, made its mark developing innovative compounds based on chiral molecules, producing safe and effective drugs that have satisfied the unmet needs of tens of thousands of patients throughout North America.
Over the past quarter-century, Sepracor's drug discovery, research and development, and corporate development and licensing efforts have yielded a series of successful and well-known brands including both drugs licensed to others—Schering-Plough for CLARINEX®; (desloratadine), Sanofi-Aventis for ALLEGRA® (fexofenadine HCl), for example—and others commercialized internally: Aptiom® (eslicarbazepine acetate) tablets, Latuda® (lurasidone HCl) tablets, Lunesta® (eszopiclone) tablets, Xopenex® (levalbuterol HCl) Inhalation Solution , Xopenex HFA® (levalbuterol tartrate) Inhalation Aerosol , Brovana® (arformoterol tartrate) Inhalation Solution, Omnaris® (ciclesonide) Nasal Spray, Zetonna® (ciclesonide) Nasal Aerosol, and Alvesco® (ciclesonide) Inhalation Aerosol.
On November 8, 2013, the U.S. Food and Drug Administration (FDA) approved Aptiom® (eslicarbazepine acetate) tablets.
As Sunovion, we will continue to discover, develop, and bring to market meaningful pharmaceutical products that advance the science of medicine, and enhance the professional's portfolio of treatment options, to improve the lives of patients, their families, and communities around the world.